T
Thomas W. Flaig
Researcher at University of Colorado Boulder
Publications - 215
Citations - 17211
Thomas W. Flaig is an academic researcher from University of Colorado Boulder. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 40, co-authored 180 publications receiving 14477 citations. Previous affiliations of Thomas W. Flaig include American Society of Clinical Oncology & Charité.
Papers
More filters
Journal ArticleDOI
Low-dose diethylstilbestrol for the treatment of advanced prostate cancer
TL;DR: Low-dose DES is safe and effective in a modern cohort of men with CRPC despite anti-androgen treatment and its potential role in the post-chemotherapy setting and the suggestion of efficacy on re-challenge merits additional consideration.
Journal Article
Silibinin suppresses CD44 expression in prostate cancer cells.
TL;DR: CD44 inhibition is one mechanism by which silibinin reduces PCa tumorigenicity, and is tested preoperatively on a pilot cohort of 6 men with PCa compared with 7 matched placebo-treated men, with immunostaining for CD44v7-10 in their prostates.
Journal ArticleDOI
Bone marrow transplantation for nonmalignant diseases.
Nabil Saba,Thomas W. Flaig +1 more
TL;DR: This work attempts to provide a comprehensive review of BMT and discusses unique features of this modality for treatment of nonmalignant disorders.
Journal ArticleDOI
Tocilizumab‐induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System
Thomas W. Flaig,Antonios Douros,Elisabeth Bronder,Andreas Klimpel,Reinhold Kreutz,Edeltraut Garbe,Edeltraut Garbe +6 more
TL;DR: The first well‐documented case of TCZ‐induced acute pancreatitis (AP) is presented and a systematic review of the literature including data from the Food and Drug Administration Adverse Event Reporting System (FAERS) database is reviewed.
Journal ArticleDOI
SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer.
Thomas W. Flaig,Catherine M. Tangen,Siamak Daneshmand,Ajjai Alva,Seth P. Lerner,M. Scott Lucia,David J. McConkey,Dan Theodorescu,Amir Goldkorn,Matthew I. Milowsky,Richard Carlton Bangs,Gary R. MacVicar,Bruno R. Bastos,Daniel L. Gustafson,Melissa Plets,Ian M. Thompson +15 more
TL;DR: Both dose-dense Methotrexate-Vinblastine-Adriamycin/doxorubicin-CISplatin and Gemcitabine-Cisplatin are accepted neoadjuvant regimens for muscle-invasive bladder cancellation.